ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,784.79
      1.43%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Neuroderm Ltd. - Ordinary Shares (NDRM)

      7. Neuroderm Ltd. - Ordinary Shares (NDRM) News

      NDRM

      NEURODERM LTD. (NDRM)

      Neuroderm Ltd. - Ordinary Shares
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:NDRM
      DateTimeSourceHeadlineSymbolCompany
      10/30/20176:10AMEdgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      10/23/20176:02AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      10/18/20178:17AMEdgar (US Regulatory)(25-NSE)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      10/18/20176:25AMEdgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      10/18/20176:23AMEdgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      10/18/20176:21AMEdgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      10/18/20176:19AMEdgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      10/18/20176:16AMEdgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      10/18/20176:12AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      10/18/20174:23AMGlobeNewswire Inc.Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDermNASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      09/12/20178:46AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      09/12/20178:37AMGlobeNewswire Inc.NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma CorporationNASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      09/11/20174:07PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      08/17/20174:02PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      08/03/20175:01PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      08/03/20174:05PMGlobeNewswire Inc.NeuroDerm Announces Second Quarter 2017 Financial ResultsNASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      08/01/20174:32PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      08/01/20174:05PMGlobeNewswire Inc.NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporat...NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      07/24/20174:31PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      07/24/20172:00AMGlobeNewswire Inc.NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in CashNASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      06/30/201712:09PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      06/27/20177:00AMGlobeNewswire Inc.Results of NeuroDerm’s ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neur...NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      06/09/20175:31PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      06/08/201712:01PMGlobeNewswire Inc.NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement DisordersNASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      06/06/20179:06AMGlobeNewswire Inc.European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy TrialNASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      06/05/201712:01PMGlobeNewswire Inc.NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parki...NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      05/30/20177:00AMGlobeNewswire Inc.NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      05/23/20177:00AMGlobeNewswire Inc.NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parki...NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      05/12/201712:34PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
      05/11/20177:00AMGlobeNewswire Inc.NeuroDerm Announces First Quarter 2017 Financial ResultsNASDAQ:NDRMNeuroderm Ltd. - Ordinary Shares
       Showing the most relevant articles for your search:NASDAQ:NDRM